Why does compounded ecnoglutide potency vary between pharmacies?

I would like to understand the process rather than be told to try harder.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

Is the standard explanation correct, and if so, what is the evidence for it?

Concretely, the distinction that governs most of this is between a preparation made for an identified patient against a prescription and a preparation made in bulk for office stock, and the two sit under different statutory provisions with different testing obligations.

A beyond-use date for a compounded multi-dose preparation is set under USP chapter provisions on the basis of microbiological risk category and, where available, supporting stability data. In practice most beyond-use dates in this space are default values from the risk-category table rather than the output of a stability study, and the two should not be read as equivalent claims.

In practice, features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.

External review of health-plan denials in the United States operates under the Affordable Care Act’s appeal provisions and, for employer self-funded plans, under ERISA; the practical significance is that an independent reviewer applies the plan’s own criteria without the plan’s involvement.

Ask for the written criteria before you submit. Everything else in the process is easier once you have them.

The relevant detail is that model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.

What a payer wants in a prior authorisation is documentation mapped to their own written criteria, in their own terms: a diagnosis code, a documented body mass index or comorbidity meeting their threshold, a record of a supervised lifestyle intervention over their specified duration, and documentation of any step-therapy agent tried and its outcome. A clinical narrative that does not map onto those fields will be denied by someone who never reads the narrative.

It helps to be literal here: 503A and 503B differ in what they are permitted to do and what they must demonstrate. A 503A pharmacy compounds against individual prescriptions, is exempt from current good manufacturing practice requirements, and is regulated primarily at state level with USP chapter compliance as the operative standard. A 503B outsourcing facility registers federally, must comply with cGMP, may prepare without patient-specific prescriptions, and is subject to FDA inspection. The practical consequence is that a 503B preparation carries release testing and a 503A preparation generally does not.

One qualification: this is a description of process, not legal or medical advice. Where a decision has legal consequences, it deserves someone whose professional obligation is to you.

If the intake did not ask about contraindications, that tells you what kind of service it is.

Concretely, a defensible telehealth encounter has identifiable features, and the absence of those features is the most useful signal available to a prospective patient.

The internal-then-external appeal path is worth pursuing further than most people do, because the external reviewer is not the plan. Internal appeals are adjudicated by the entity that issued the denial; external review is conducted by an independent organisation against the same criteria, and it overturns a non-trivial fraction of denials.

USP General Chapter <797> on sterile preparation compounding sets the microbiological risk categories and default beyond-use dates that most compounded beyond-use dating in this space derives from.

Worth noting that regulatory status in this area has changed repeatedly over the past three years, so any answer including a date should be checked against the current position.

Model twelve months, not one. The fee structures are designed to be compared monthly.

On the detail: prior authorisation is an adjudication against written criteria, and the criteria are usually obtainable. Requesting them before submitting is the single highest-yield step in the process.

Denials come in two flavours and it is worth identifying which you have. A criteria denial means the submission did not evidence something the criteria require, and it is fixed by supplying the evidence. A formulary exclusion means the plan does not cover the drug at any level for any indication, and no amount of clinical documentation changes it — the route there is a formulary exception request or an employer-level appeal.

Verify accreditation on the accreditor’s register rather than on the pharmacy’s website. It takes a minute.